Image and intracavitary electrocardiogram-guided arm port placement in colorectal cancer: A retrospective comparative study

Table 1 Comparison of baseline characteristics between groups, n (%)

Characteristics	Experimental group (n = 103)	Control group (n = 113)	Statistics	P value
General characteristics
Age (year), mean ± SD	58.3 ± 12.1	59.6 ± 11.8	t = 0.812	0.418
Gender			χ2 = 0.046	0.831
Male	56 (54.4)	63 (55.8)
Female	47 (45.6)	50 (44.2)
BMI (kg/m²)	23.4 ± 3.2	22.9 ± 3.5	t = 1.079	0.282
Disease characteristics
Tumor location			χ2 = 0.094	0.759
Colon	58 (56.3)	66 (58.4)
Rectum	45 (43.7)	47 (41.6)
Tumor stage			χ2 = 0.286	0.867
Stage II	25 (24.3)	30 (26.5)
Stage III	49 (47.6)	50 (44.2)
Stage IV	29 (28.1)	33 (29.3)
Previous surgery	67 (65.0)	76 (67.3)	χ2 = 0.122	0.727
Treatment-related
Chemotherapy regimen			χ2 = 0.214	0.899
FOLFOX	47 (45.6)	55 (48.7)
FOLFIRI	33 (32.0)	33 (29.2)
Others	23 (22.4)	25 (22.1)
Chemotherapy cycles, mean ± SD	6.8 ± 2.3	6.5 ± 2.6	t = 0.908	0.365
Venous access site			χ2 = 0.152	0.927
Basilic vein	70 (68.0)	74 (65.5)
Brachial vein	20 (19.4)	24 (21.2)
Cephalic vein	13 (12.6)	15 (13.3)
Laboratory parameters
Albumin (g/L), mean ± SD	35.6 ± 4.7	36.2 ± 4.4	t = 0.982	0.327
Hemoglobin (g/L), mean ± SD	112.3 ± 18.5	109.8 ± 19.3	t = 0.986	0.325
Coagulation parameters
PT (second), mean ± SD	12.3 ± 1.1	12.5 ± 1.0	t = 1.451	0.149
APTT (second), mean ± SD	28.6 ± 3.2	29.1 ± 3.5	t = 1.118	0.265
PLT (× 109/L), mean ± SD	182 ± 56	175 ± 62	t = 0.888	0.376

BMI: Body mass index; FOLFOX: Folinic acid, fluorouracil, and oxaliplatin; FOLFIRI: Folinic acid, fluorouracil, and irinotecan; PT: Prothrombin time; APTT: Activated partial thromboplastin time; PLT: Platelet count.